June 19, 2020 / 6:30 PM / 22 days ago

BRIEF-Roche Gets FDA Approval For Cobas EZH2 Mutation Test As Companion Diagnostic For Tazverik Developed By Epizyme

June 19 (Reuters) - Roche Holding AG:

* ROCHE RECEIVES FDA APPROVAL FOR COBAS EZH2 MUTATION TEST AS A COMPANION DIAGNOSTIC FOR PATIENTS WITH FOLLICULAR LYMPHOMA

* ROCHE - COBAS EZH2 MUTATION TEST EXPECTED TO BE COMMERCIALLY AVAILABLE IN U.S. LATER THIS YEAR

* ROCHE - U.S. FDA APPROVAL OF COBAS EZH2 MUTATION TEST AS A COMPANION DIAGNOSTIC FOR TAZVERIK DEVELOPED BY EPIZYME Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below